Loading....
The activities of the Let’s Talk Prostate Cancer (LTPC) Expert Group are funded by Astellas Pharma Inc., Amgen Inc and Pfizer Inc, which collectively contribute to and support the objectives of the Expert group.
Astellas Pharma Inc. have full and exclusive editorial control over the LTPC Website

INCIDENCE

Prostate cancer incidence in Finland is higher than the European average of  153.9 per 100,000 population, at a rate of 206.2 per 100,000.1 Screening for prostate cancer is not recommended at the population level.2

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)

2 Cancer Society of Finland. Cancer screenings. Accessible at https://www.cancersociety.fi/publications/reports/cancer-in-finland-2016/cancer-screenings/ (last accessed March 2022)

Estimated prostate cancer incidence 2020
(crude rate per 100,000 population)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)

MORTALITY

Mortality rates for prostate cancer in Finland are slightly higher than the EU27 average of 32.1 per 100,000 population, at a rate of 33 per 100,000.1

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed February 2022

Prostate cacner mortality 2020
(crude rate per 100,000 population)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)

SURVIVAL

From 2010-2014, the 5-year net survival rate for prostate cancer patients in Finland was the fourth-highest in the EU, behind Belgium, Lithuania and Cyprus.1

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

Prostate cacner age-standardised 5-year net survival (%)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

NATIONAL POLICES

In Finland, prostate cancer is mentioned in the national Cancer prevention, early detection and developing rehabilitation support plan (2014-2025).

CLINICAL GUIDELINES

Finland’s ‘Current Care Guidelines’ are independent, evidence-based clinical practice guidelines and cover important issues related to Finnish health, medical treatment as well as prevention of diseases. The 2014 Prostate Cancer guidelines set out the recommended care pathway, includes patient access to*:

Review by a multidisciplinary team
Support from a specialist nurse
Holistic needs assessment
A tailored treatment plan
Nutrition and exercise advice
Psychological support
Regular care reviews

Legend:

Recommendation included

Recommendation not included

*For a detailed explanation of the different patient support categories included in this scorecard, please follow the link.

CANCER CARE

Access to Specialists

The number of urologists per citizen in Finland is relatively low, with 47,272 citizens to every 1 urologist.1 This puts Finland in the bottom 4 EU countries in terms of access to urologists, behind Ireland,2 the UK3 and Denmark.4

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 European Society of Residents in Urology (ESRU). Finland. March 2018. Accessible at https://esru.eu/?q=finland (last accessed March 2022)

2 European Society of Residents in Urology (ESRU). Ireland. March 2018. Accessible at https://esru.eu/?q=ireland (last accessed March 2022)

3 Palmer, M and Taylor, C. British Association of Urological Surgeons and The Specialist Advisory Committee in Urology: Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/
publications/Workforce_Report_Sep%202018%20ver%201.1.pdf
(last accessed March 2022)

4 European Society of Residents in Urology (ESRU). Denmark. March 2018. Accessible at https://esru.eu/?q=denmark (last accessed  March 2022)

Cost of cancer

In 2018, the direct cost of cancer in Finland was €153 per person,1 on average with the European average of €154 per person.2 Other Nordic countries, such as Denmark and Sweden, spend €259 and €187 respectively.1 Whilst a number of factors contribute to improved outcomes for those affected by prostate cancer, studies have shown that those countries that invest more in cancer care tend to achieve better outcomes for patients.3

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
2 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022) – average calculated from data included for individual countries.
3 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7.

Cancer medicines spend

Finland spends €60 per capita on cancer medicines, similar to Sweden which spends €57 per capita.1 Austria spends the highest amount per capita on cancer medicines in the EU, at €108 per capita.1 At the other end of the scale, Greece and Estonia only spend €4 per capita.1

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

Approximate number of inhabitats per urologist - 2018*

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

*Different data sources were used for Belgium, Hungary, Italy, Romania and the UK, which may use data from different years. See references below. No data was found for Cyprus, Luxembourg, Malta and Slovakia.

European Society of Residents in Urology (ESRU). Countries. March 2018. Accessible at https://esru.eu/?q=countries (last accessed March 2022)
Federal Public Service of Public Health, Safety of the Food Chain and the Environment. HWF STATAN 2019 (detailed statistics). 2019. Accessible at https://organesdeconcertation.sante.belgique.be/fr/documents/hwf-statan-2019-statistiques-detaillees (last accessed March 2022)
Boszormenyi-Nagy, G. Report on urological inpatient care based on 2018 data. Urologia Hungarica. Accessible at http://urologiahungarica.hu/index.php/2020/05/12/beszamolo-az-urologiai-fekvobeteg-ellatasrol-a-2018-as-adatok-alapjan/ (last accessed March 2022)
I.Stat. Personale sanitario. Accessible at http://dati.istat.it/Index.aspx?DataSetCode=DCIS_PERS_SANIT (last accessed March 2022)
Institutul National De Statistica. Activitatea Unitatilor Sanitare in Anul 2019. 2020. Accessible at https://insse.ro/cms/sites/default/files/field/publicatii/activitatea_unitatilor_sanitare_anul_2019.pdf (last accessed March 2022)
United Nations, Population Division, Department of Economic and Social Affairs. World Population Prospects 2019. Accessible at https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/EXCEL_FILES/1_Population/
WPP2019_POP_F01_1_TOTAL_POPULATION_BOTH_SEXES.xlsx
(last accessed March 2022)
British Association of Urological Surgeons and The Specialist Advisory Committee in Urology. Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/publications/
Workforce_Report_Sep%202018%20ver%201.1.pdf
(last accessed March 2022)

Direct health cost of cancer per person - 2018 (€)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

Per capita cost of cancer medicines - 2018 (€)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

ORGANISATIONS

Patient organisations

The main prostate cancer patient organisation in Finland is:

PROPO
https://www.propo.fi/

Reference Number: ONC_2021_0135_BE
Date of preparation: January 2022

Europe Digital Atlas